SALA, GIANLUCA
 Distribuzione geografica
Continente #
NA - Nord America 1.887
EU - Europa 1.343
AS - Asia 937
SA - Sud America 96
AF - Africa 8
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.275
Nazione #
US - Stati Uniti d'America 1.882
SG - Singapore 494
IT - Italia 420
IE - Irlanda 297
CN - Cina 233
SE - Svezia 184
DE - Germania 91
BR - Brasile 90
UA - Ucraina 86
TR - Turchia 68
FR - Francia 65
IN - India 47
GB - Regno Unito 46
RU - Federazione Russa 43
VN - Vietnam 37
FI - Finlandia 30
HK - Hong Kong 29
BE - Belgio 19
AT - Austria 18
NL - Olanda 11
CZ - Repubblica Ceca 9
GR - Grecia 7
AE - Emirati Arabi Uniti 5
CA - Canada 4
CH - Svizzera 4
IL - Israele 3
JP - Giappone 3
ZA - Sudafrica 3
AU - Australia 2
BG - Bulgaria 2
IQ - Iraq 2
LK - Sri Lanka 2
MY - Malesia 2
PE - Perù 2
RS - Serbia 2
TW - Taiwan 2
UZ - Uzbekistan 2
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
DK - Danimarca 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
JM - Giamaica 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
TH - Thailandia 1
TN - Tunisia 1
VE - Venezuela 1
Totale 4.275
Città #
Chandler 411
Singapore 307
Dublin 294
Jacksonville 178
Princeton 114
The Dalles 106
Ashburn 92
Ann Arbor 85
Santa Clara 76
Chieti 62
Beijing 59
Pescara 58
Altamura 52
Boardman 48
Nanjing 45
Dearborn 44
Izmir 36
Dong Ket 35
Wilmington 34
Los Angeles 28
Hong Kong 27
Southend 22
New York 21
Munich 20
Brussels 19
Washington 18
Cambridge 16
Seattle 15
Nuremberg 14
Nanchang 13
Pune 13
Collecorvino 12
Lappeenranta 12
Hebei 11
Mcallen 10
Norwalk 10
Woodbridge 10
Frankfurt am Main 9
Milan 9
Helsinki 8
Montesilvano 8
Shenyang 8
Castignano 7
Falls Church 7
Zhengzhou 7
Brno 6
Fairfield 6
Kunming 6
Rome 6
Tianjin 6
Vienna 6
Dubai 5
Finale Ligure 5
Moscow 5
Shijiazhuang 5
Camerino 4
Campinas 4
Houston 4
Jinan 4
London 4
L’Aquila 4
Newark 4
Redwood City 4
Romola 4
Stockholm 4
São Paulo 4
Tappahannock 4
Belo Horizonte 3
Brasília 3
Changsha 3
Città Sant'Angelo 3
Düsseldorf 3
Guangzhou 3
Hefei 3
Jiaxing 3
Lauterbourg 3
Napoli 3
Olomouc 3
Parma 3
Perugia 3
Presidente Prudente 3
Rio de Janeiro 3
Salvador 3
Silvi 3
Tel Aviv 3
Toronto 3
Valdagno 3
Ancona 2
Andover 2
Baghdad 2
Belgrade 2
Cattolica 2
Chicago 2
Chongqing 2
Civitanova Marche 2
Colombo 2
Cosenza 2
Dübendorf 2
Edinburgh 2
Espoo 2
Totale 2.680
Nome #
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance 137
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 130
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 126
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 110
ERBB3 BINDING ANTIBODY 104
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 103
ABCC3 is a novel target for the treatment of pancreatic cancer 103
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 101
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 101
Repurposing a psychoactive drug for children with cancer: p27 Kip1-dependent inhibition of metastatic neuroblastomas by Prozac 99
CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs–Letter 98
BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages 96
Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer 96
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 95
Therapeutic efficacy of the novel stimuli-sensitive nano-ferritins containing doxorubicin in a head and neck cancer model 94
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 89
Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer 89
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 86
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer 82
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer 79
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 79
Humanized anti-bag3 antibodies 77
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine 77
The role of phospholipase Cγ1 in breast cancer and its clinical significance 76
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 75
Breast cancer in the era of integrating "Omics" approaches 75
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies 74
The G-protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1 74
Phospholipase Cgamma1 is required for metastasis development and progression 71
BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration 69
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 68
Antibody-drug conjugates: The new frontier of chemotherapy 67
The E27 β2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males 66
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 66
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 65
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 64
Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation 64
HER-3: Hub for escape mechanisms 63
The role of phosphoinositide 3-kinase C2α in insulin signaling 60
Endosialin-binding antibody 57
Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines 56
Engineered human nanoferritin bearing the drug genz-644282 for cancer therapy 56
Feedback inhibition by RALT controls signal output by the ErbB network 54
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 53
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 53
Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control 53
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 52
P63 role in breast cancer 52
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools 51
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 51
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth 49
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors 48
Negative regulation of receptor tyrosine kinase signals 47
Role of BAG3 in cancer progression: A therapeutic opportunity 46
A phosphoinositide 3-kinase/phospholipase cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation 46
Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin 45
MYC regulates metabolism through vesicular transfer of glycolytic kinases 42
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer 37
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET 35
Effects of an ErbB-3 antibody, MP-RM-1, on tumor growth and ligand-dependent and -independent activation of ErbB-3/akt signaling 35
LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma 34
Therapeutic potential of antibody‐drug conjugate‐based therapy in head and neck cancer: A systematic review 27
The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma 26
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans 26
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target 26
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers 22
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate 20
null 20
Cold atmospheric plasma activated media selectively affects human head and neck cancer cell lines 18
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth 12
Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma 9
A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy 9
Human head and neck cancer cell lines response to cold atmospheric plasma activated media is affected by the chemistry of culture media 8
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 3
Totale 4.626
Categoria #
all - tutte 23.119
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.119


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202076 0 0 0 0 0 0 0 0 0 0 67 9
2020/2021337 39 3 60 7 23 60 24 15 16 34 9 47
2021/2022333 15 2 5 62 18 12 13 23 29 20 28 106
2022/20231.065 94 175 71 124 92 176 49 89 129 12 38 16
2023/2024638 38 15 64 33 36 214 97 26 5 25 13 72
2024/20251.362 60 301 242 66 45 74 71 74 218 130 81 0
Totale 4.626